TRML Key Statistics, Chart & Performance
The current stock price of TRML is 47.98 USD. In the past month the price decreased by -0.37%. In the past year, price increased by 82.43%.
TRML Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.4 | 390.84B | ||
| AMGN | AMGEN INC | 14.95 | 176.09B | ||
| GILD | GILEAD SCIENCES INC | 14.78 | 150.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.86 | 118.29B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767.46 | 51.71B | ||
| INSM | INSMED INC | N/A | 36.65B | ||
| NTRA | NATERA INC | N/A | 33.73B | ||
| BIIB | BIOGEN INC | 10.77 | 26.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.07 | 21.67B | ||
| INCY | INCYTE CORP | 16.32 | 20.57B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About TRML
Company Profile
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. The company is headquartered in New York City, New York and currently employs 76 full-time employees. The company went IPO on 2021-05-07. The firm is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. The company is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.
Company Info
TOURMALINE BIO INC
27 West 24th Street, Suite 702
New York City NEW YORK US
Employees: 74
Phone: 15023989250.0
TOURMALINE BIO INC / TRML FAQ
Can you describe the business of TOURMALINE BIO INC?
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. The company is headquartered in New York City, New York and currently employs 76 full-time employees. The company went IPO on 2021-05-07. The firm is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. The company is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.
What is the current price of TRML stock?
The current stock price of TRML is 47.98 USD.
What is the dividend status of TOURMALINE BIO INC?
TRML does not pay a dividend.
How is the ChartMill rating for TOURMALINE BIO INC?
TRML has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is TOURMALINE BIO INC (TRML) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TRML.
What is the next earnings date for TRML stock?
TOURMALINE BIO INC (TRML) will report earnings on 2026-03-11, after the market close.
Who owns TOURMALINE BIO INC?
You can find the ownership structure of TOURMALINE BIO INC (TRML) on the Ownership tab.
TRML Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TRML. When comparing the yearly performance of all stocks, TRML is one of the better performing stocks in the market, outperforming 96.89% of all stocks.
TRML Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRML. TRML has a great financial health rating, but its profitability evaluates not so good.
TRML Financial Highlights
Over the last trailing twelve months TRML reported a non-GAAP Earnings per Share(EPS) of -3.43. The EPS increased by 6.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.79% | ||
| ROE | -34.07% | ||
| Debt/Equity | 0 |
TRML Forecast & Estimates
15 analysts have analysed TRML and the average price target is 48.96 USD. This implies a price increase of 2.04% is expected in the next year compared to the current price of 47.98.